Iododeoxyuridine labelling of S-phase fraction in fine needle aspirates from breast carcinomas

R A Maas, P F Bruning, A J Breedijk, J L Peterse

Abstract
The suitability of measuring the S-phase fraction in human breast cancer by labelling tumour cells from fine needle aspirates (FNAs) in vitro with iododeoxyuridine (IdU) was studied in 11 patients. The S-phase fraction was measured both in preoperative FNAs labelled in vitro with IdU, and in FNAs taken from the same tumour when surgically removed after intravenous administration of IdU. Frozen sections were also immunostained for incorporated IdU. The mean S-phase fraction measured in FNAs after in vitro or in vivo labelling and in sections after in vivo labelling was 4.0, 3.6, and 3.1, respectively. Results of in vitro and in vivo labelling of FNAs with IdU were similar. However, as the S-phase fraction in breast cancer is generally low, the variation between the different measurements is too large; therefore, the S-phase fraction is not a suitable indicator of response to treatment.


Keywords: breast cancer, fine needle aspirates, S-phase fraction.

Decreasing proliferative activity in tumours could be used as an early indication of response to systemic treatment. Changes in S-phase fraction as a measure of the proliferative activity could be monitored in sequentially obtained fine needle aspirates (FNAs). Immunostaining of iododeoxyuridine (IdU) incorporated into the DNA in the S-phase of the cell cycle offers a sensitive and specific method to assess S-phase fraction in FNAs from breast tumours. In vivo labelling of tumour cells requires the intravenous administration of IdU. Apart from the discomfort to the patient and costs involved, IdU administration may in turn cause further mutation. Moreover, the optimal timing of IdU administration varies from patient to patient. In vitro labelling with IdU is an attractive alternative.

Methods
IdU labelling
The S-phase fraction was measured in 17 patients with primary breast cancer. FNAs were taken from the primary breast carcinomas on the day before surgical removal of the tumour. Viable carcinoma cells were counted using the trypan blue exclusion test. The tumour cells were labelled in vitro by being incubated at 37°C for two hours in DMEM culture medium (Gibco BRL, Breda, The Netherlands) containing 10% fetal calf serum (Gibco BRL) and 10 μM IdU (Sigma, Axel, The Netherlands). Approximately six hours before surgery the patients received an intravenous infusion of 100 mg IdU in 50 ml. Directly after surgical removal of the tumour a second FNA was taken for the analysis of in vivo labelling. FNAs were washed in phosphate buffered saline (PBS), resuspended in 70% alcohol and stored at 4°C pending analysis. Tumour tissue was snap frozen in liquid nitrogen until further processing.

Permission to administer IdU was obtained from the Medical Ethical Committee of the Antoni van Leeuwenhoekhuis. Informed consent was obtained from each patient.

Immunocytochemical staining for IdU
Cytospin preparations were prepared, dried and washed in PBS. After being washed in PBS, frozen tumour sections were treated in the same way as the cytospin preparations. All samples were incubated in 95% formamide in PBS at 70°C for 45 minutes, washed three times for five minutes in 0.1 M Tris/HCl (pH 7.6) supplemented with 5% Tween 20, followed by a 10 minute wash in Tris/HCl (pH 7.6). After preincubation for 15 minutes in PBS supplemented with 0.5% Tween 20, 0.1% bovine serum albumin (BSA) and 10% normal rabbit serum, the preparations were incubated at room temperature with anti-IdU murine

4 Bruning, Netherlands Pathology of Department Amsterdam. The 18 October 1995.
5 R A Maas, P F Bruning, A J Breedijk, J L Peterse
6 Department of Pathology, Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis, Amsterdam, The Netherlands
7 R A Maas
8 A J Breedijk
9 J L Peterse
10 Department of Medical Oncology P F Bruning
11 Correspondence to: Dr P F Bruning, Netherlands Cancer Institute, Department of Medical Oncology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
12 Accepted for publication 18 October 1995
monoclonal antibody (Becton Dickinson, Etten-Leur, The Netherlands) diluted 1 in 200 in PBS/BSA/Tween/normal rabbit serum. After two washes in PBS/BSA the preparations were incubated in biotinylated rabbit antimouse (Dako, Glostrup, Denmark), diluted 1 in 1000 in PBS/BSA/Tween/normal rabbit serum. Preparations were then washed twice in PBS/BSA followed by a 30 minute incubation with avidin/ biotin horse radish peroxidase complex (Dako). After being washed twice in PBS/BSA and once in 0.1 M Tris/HCl (pH 7.4), the preparations were incubated with diaminobenzidine/imidazole/hydrogen peroxide in the dark at room temperature for six minutes. Samples were then washed in PBS and staining was enhanced by incubation in copper sulphate (0.5% CuSO4.5H2O, 0.9% NaCl) at room temperature for five minutes. Finally, the preparations were rinsed in aquadest and a general nuclear staining was performed by incubation in haematoxylin for one to three minutes, followed by a four minute rinse in running water. The S-phase fraction was determined independently by two investigators. At least 1000 tumour nuclei were counted per specimen. Lines were drawn randomly on the glass covering the cell suspension and tissue section, and the neighbouring microscopic fields were analysed.

Results
The S-phase fraction was determined in 11 of the 17 patients. Too few viable tumour cells were present in one of the two FNAs from the other six. Three different methods were used: (1) in vitro labelling with IdU; (2) in vivo labelling with IdU (FNAs from surgically resected specimens); and (3) in vivo labelling with IdU (measured in frozen tumour sections). IdU positive and IdU negative cells could be distinguished easily in FNA cytospin preparations and the frozen sections (fig 1). Evaluation of S-phase fraction by different observers resulted in excellent conformity, with <5% interobserver variation. The data obtained in the 11 patients are summarised in fig 2. In one patient a large difference was found between the two FNAs and the frozen section, the latter having a much higher S-phase fraction (3, 6, and 21, respectively). This was due to the large number of dead cells present. The mean (SD) S-phase fraction in FNAs in the other 10 patients was 4.0 (2.5)% after in vitro labelling and 3.6 (1.9)% after in vivo labelling; analysis of tissue sections yielded a mean S-phase fraction of 3.1 (1.7)%. The mean S-phase fraction values were not significantly different (paired t test). The mean difference between the measurements on FNAs obtained prior to surgery and those taken from the surgical specimen was 2.6%.

Discussion
Theoretically, changes in the S-phase fraction, monitored in sequentially obtained FNAs, could act as early indicators of response to therapy, and can also provide prognostic

Figure 1  Tumour section and two FNAs from the same patient. (A) FNA after in vitro labelling with IdU; (B) FNA after in vivo labelling with IdU; (C) section after in vivo labelling with IdU.

Figure 2  S-phase fraction in 11 patients with breast cancer measured in FNAs after in vitro or in vivo labelling with IdU, or measured on frozen sections after in vivo labelling with IdU.
Sclerosing lymphocytic lobulitis in the male breast

A H S Lee, B Zafrani, G Kafiri, S Rozan, R R Millis

Abstract
Sclerosing lymphocytic lobulitis is an inflammatory disorder of the breast that is well recognised in women. It has only been reported previously in two men; two further men with the condition are described here. Both presented with a breast mass, and one was an insulin dependent diabetic. Biopsy specimens from both patients showed circumscribed perivascular and, to a lesser extent, periducal collections of B and T lymphocytes. Sclerosing lymphocytic lobulitis in the female breast shows predominantly perilobular inflammation. The predominantly perivascular distribution in men is consistent with the relative paucity of epithelium in the male breast. Interlobular fibrosis with epithelioid fibroblasts was also present. (J Clin Pathol 1996;49:609–611)

Keywords: breast, male, sclerosing lymphocytic lobulitis, inflammation.

Sclerosing lymphocytic lobulitis is a recently recognised disorder of the breast characterised by perilobular and perivascular aggregates of B and T lymphocytes, with increased expression of class II major histocompatibility antigens by the lobular and ductal epithelium, fibrosis and lobular atrophy.1,2 It is thought to be of autoimmune aetiology and is associated with other autoimmune diseases, particularly diabetes mellitus. The condition is well recognised in women, but has been reported in only two men.3 We describe two additional male patients in whom the perivascular and perilobular inflammation has been characterised immunohistochemically.

Case reports
Patient 1 was a 47 year old Algerian man who presented with a 15 mm mass in the right breast. He had had insulin dependent diabetes mellitus for 31 years, but no history of other autoimmune diseases. Patient 2 was a 53 year old Greek man who presented with a poorly defined 5 cm breast mass. He did not have diabetes mellitus nor any other autoimmune disease, nor a family history of diabetes.

Imperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital, London A H S Lee R R Millis
Section Medicale et Hospitaliere, Institut Curie, Paris, France B Zafrani S Rozan
Histopathology Department, Hippocrature General Hospital, Athens, Greece G Kafiri

Correspondence to: Dr A H S Lee, University Department of Pathology, Mailpoint 813, Level E, South Block, Southampton General Hospital, Southampton SO16 6YD.
Accepted for publication 20 February 1996

2 Remvikos Y, Bezeubroc P, Zajdela A, Voilmont N, Magdele-


This study was supported by Imperial Cancer Research Fund and London Fund.
Iododeoxyuridine labelling of S-phase fraction in fine needle aspirates from breast carcinomas.

R A Maas, P F Bruning, A J Breedijk and J L Peterse

doi: 10.1136/jcp.49.7.607

Updated information and services can be found at:
http://jcp.bmj.com/content/49/7/607

**Email alerting service**

These include:

- Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/